ClinicalTrials.gg
CompletedNCT00275457Updated Oct 31, 2013

Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients

A Phase 3 interventional study of pramipexole in Restless Legs Syndrome, sponsored by Boehringer Ingelheim. Completed at 34 sites in 5 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-10-31.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
346
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing pramipexole in Restless Legs Syndrome — none open to participants now, 1 under way, none of them phase 3. Pramipexole · Restless Legs Syndrome.

Enrollment
4th of 17
346 · median 154
Started
2002
with 1 other
Phase 3
6 of 17
none open now
Registered
6th of 17
by date
Lead sponsor
12 of 17
Boehringer Ingelheim

Among the 17 studies testing pramipexole in Restless Legs Syndrome, this one is the 4th largest by enrollment, is one of 2 that started in 2002, is one of 6 in phase 3, and was the 6th registered.

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Open to participants now

None of the 17 studies testing pramipexole in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →

About pramipexole

Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing pramipexole in Restless Legs Syndrome as a file.
02

Study summary

To evaluate safety and efficacy of pramipexole in the treatment of patients suffering from moderate to severe RLS over 6 weeks under double blinded conditions followed by a 46 week open label or double blind extension.

Read the detailed description

To evaluate safety and efficacy of pramipexole in the treatment of patients suffering from moderate to severe RLS over 6 weeks under double blinded conditions followed by a 46 weeks open label or double blind extension

Study Hypotheses:

Null hypothesis: No difference between pramipexole and placebo in RLSRS total score from baseline and no difference in the CGI-I responder rates at the end of the 6 weeks double-blind treatment.

Comparison(s):

Pramipexole vs. Placebo

03

Conditions studied

  • Restless Legs Syndrome
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female out-patients aged 18-80
  2. Diagnosis of idiopathic RLS according to the Clinical RLS criteria of the International RLS Study Group. All of the four criteria must be present:

    • Irresistible urge to move usually associated with sensory complaints of the lower limbs
    • Motor restlessness
    • Worsening of the symptoms at rest with at least partial and temporary relief by activity
    • Increased severity in the evening or at night
  3. RLS rating scale for severity score > 15
  4. RLS symptoms present at least 2 to 3 days per week within in the last 3 months
  5. Written consistent with ICH/GCP and local legislation given prior to any study procedures
  6. Ability and willingness to comply with study treatment regimen and to attend study assessments

Exclusion criteria

Exclusion criteria:

  1. Women of , who do not use adequate protection such as barrier protection, intrauterine device, or hormonal (oral or subcutaneous) or women less than 6 months after last menses, surgically sterilised, oophorectomised or hysterectomised less than 3 months after operation and not using adequate protection or women neither using adequate protection nor being postmenopausal and their partner is not sterilised at least 6 months post operation or does not use condom, or any women not having negative serum pregnancy test at screening
  2. Males not using an adequate form of contraception (condom, sterilisation at least 6 months post operation)
  3. Patients who are breastfeeding
  4. Concomitant or previous pharmacologically therapy of RLS as follows:

    • Any intake of levodopa within 5 days prior to baseline visit (V2)
    • Any intake of dopamine agonists within 14 days prior to baseline visit (V2)
    • History of any intake of pramipexole
  5. Current (less than 14 days before treatment with trial medication or concomitant) treatment with medication or dietary supplements, which could significantly influence RLS symptoms - withdrawal symptoms caused by stopping any of the drugs above
  6. Confirmed diagnose of diabetes mellitus requiring insulin therapy
  7. renal disease or creatinine higher than (ULN) at screening
  8. Clinically significant hepatic disease or sGPT > 2 times the upper limit of normal range at screening
  9. Clinical or laboratory signs of microcytic anaemia at the investigators discretion
  10. Any of the following lab results at screening:

    • or erythrocyte count below lower limit of normal (LLN)
    • Basal TSH, T3 or T4 clinically significantly (at the investigator's discretion) out of normal range at screening (if not caused by substitution therapy according the investigator's opinion)
  11. Other clinically significant metabolic-endocrine, haematological, gastro-intestinal disease or pulmonary disease. Poorly controlled cardiovascular disease
  12. History or clinical signs of peripheral neuropathy (PNP) of any origin in physical, neurological examination, myelopathy or multiple sclerosis or any other neurological disease, with potential to secondarily cause RLS symptoms
  13. Presence of any other sleep disorder, such as, REM sleep behaviour disorder, narcolepsy or sleep apnoea syndrome
  14. History of Schizophrenia or any psychotic disorder, history of mental disorders due to a general medical condition or any present axis I psychiatric disorder according DSM IV requiring any medical therapy or history of or alcohol abuse or drug addiction within the last 2 years before screening
  15. Participation in a drug study within two months prior to the start of this study
  16. History of or clinical signs for any form of epilepsy or seizures apart from fever related seizures in early childhood
  17. History of or clinical signs of malign neoplasm
  18. Patients on a shift-work-schedule, or who are otherwise unable to follow a regular sleep-wake cycle enabling use of study medication at times indicated
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double
Enrollment
346 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Mean change from baseline to week 6 on the RLSRS +

  2. CGI-I responders (much and very much improved)

Secondary outcomes

  1. RLRS responders, CGI, PGI responders, EPSS, QoL (SF-36) VAS severity of RLS

07

Study locations

34 sites
  • Univ.-Klinik für Neurologie
    Graz, 8036, Austria
  • Univ.-Klinik für Neurologie
    Innsbruck, 6020, Austria
  • AKH der Stadt Linz
    Linz, 4021, Austria
  • Confraternität Privatklinik
    Wien, 1080, Austria
  • AKH Universitätsklinik für Psychiatrie
    Wien, 1090, Austria
  • Sonderkrankenanstalt für neurologischen und
    Wien, 1130, Austria
  • Wilhelminenspital der Stadt Wien
    Wien, 1160, Austria
  • Boehringer Ingelheim Investigational Site
    Bad Dürrheim-Sunthausen, 78073, Germany
  • Boehringer Ingelheim Investigational Site
    Bad Krozingen, 79189, Germany
  • Boehringer Ingelheim Investigational Site
    Berlin, 10625, Germany
  • emovis GmbH
    Berlin, 10629, Germany
  • Facharzt für Neurologie
    Emmendingen, 79312, Germany
  • Boehringer Ingelheim Investigational Site
    Kehl, 77694, Germany
  • ClinPharm International GmbH & Co. KG
    Leipzig, 04229, Germany
  • Universitätsklinikum Giessen und Marburg
    Marburg, 35039, Germany
  • Boehringer Ingelheim Investigational Site
    Beek en Donk, 5741 AR, Netherlands
  • Boehringer Ingelheim Investigational Site
    Den Haag, 2585 LJ, Netherlands
  • Boehringer Ingelheim Investigational Site
    Deurne, 5751 XJ, Netherlands
  • Boehringer Ingelheim Investigational Site
    Ewijk, 6644 CL, Netherlands
  • Boehringer Ingelheim Investigational Site
    Lichtenvoorde, 7131 CM, Netherlands
  • Boehringer Ingelheim Investigational Site
    Rijswijk, 2281 AK, Netherlands
  • Boehringer Ingelheim Investigational Site
    Roelofarendsveen, 2371 RB, Netherlands
  • Boehringer Ingelheim Investigational Site
    Rotterdam, 3082 DC, Netherlands
  • Boehringer Ingelheim Investigational Site
    Hamar, N-2317, Norway
  • Boehringer Ingelheim Investigational Site
    Oslo, N-0159, Norway
  • Boehringer Ingelheim Investigational Site
    Oslo, N-0303, Norway
  • Boehringer Ingelheim Investigational Site
    Tønsberg, N-3111, Norway
  • Boehringer Ingelheim Investigational Site
    Göteborg, 413 45, Sweden
  • Stockholms Neuro Center
    Stockholm, 112 81, Sweden
  • Neurologkliniken
    Stockholm, 141 86, Sweden
  • Boehringer Ingelheim Investigational Site
    Uppsala, 751 85, Sweden
  • Läkarhuset Vällingby
    Vällingby, 162 68, Sweden
  • Boehringer Ingelheim Investigational Site
    Västra Frölunda, 421 30, Sweden
  • Boehringer Ingelheim Investigational Site
    Örebro, 701 85, Sweden
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2002, a primary completion of Apr 2004 and a completion of Apr 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2006
First posted
Jan 12, 2006
Start
Oct 2002
Primary completionActual
Apr 2004
Completion
Apr 2004
Last update
Oct 31, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00275457
First posted
Jan 12, 2006
Start date
Oct 2002
Primary completion
Apr 2004
Completion
Apr 2004
Last update
Oct 31, 2013

Study contacts

Boehringer Ingelheim Study Coordinator
study chair · B.I. Pharma GmbH & Co. KG
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramipexole

Start the discussion